June 16 2020

Stayble’s clinical phase 2b study has started

Stayble announces today, June 16, 2020, that the Company’s clinical phase 2b study with STA363 has started with the first clinic in Russia being initiated and now recruiting patients. STA363 is targeting patients suffering from chronic low back pain caused by disc degeneration.

The primary goal of the phase 2b trial is to demonstrate safety, tolerability and a clinically relevant reduction in pain in patients. The study will include some 100 patients and will be conducted at about 20 clinical sites in the Netherlands, Russia and Spain.

CEO Andreas Gerward comments: The initiation of the trial according to plan during Q2 despite the challenges of the COVID-19 pandemic is a great achievement of our team and our collaboration partners. We are now looking forward to additional site initiations, recruitment of patients and treatment of the first patients.

For more information
Andreas Gerward, CEO Stayble Therapeutics AB
andreas.gerward@stayble.se, +46 730 808 397

About Stayble Therapeutics AB
Stayble is a clinical stage pharmaceutical company developing the injection treatment STA363 for disc-related low back pain. The treatment is aimed at patients whose back pain persists after physiotherapy and painkillers. The injection is given once and the effect is expected to remain throughout the entirety of the patient’s life and to require minimal rehabilitation. The Company’s focus is set upon the continued clinical development of the upcoming clinical phase 2b study. Stayble’s vision is to develop STA363 as a new standard treatment for patients suffering from chronic disc-related low back pain.

Mangold Fondkommission AB is the Company’s Certified Adviser and can be reached at +46 (0)8 503 015 50 or e-mail ca@mangold.se.

The information above was provided by Stayble Therapeutics AB according to EU Market Abuse Regulations. The information was provided, through the above contact person, for publication on June 16, 2020 at 16:00 CEST.